GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (NAS:ORGS) » Definitions » Shiller PE Ratio

Orgenesis (Orgenesis) Shiller PE Ratio : (As of Apr. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orgenesis Shiller PE Ratio Historical Data

The historical data trend for Orgenesis's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Shiller PE Ratio Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Orgenesis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orgenesis's Shiller PE Ratio

For the Biotechnology subindustry, Orgenesis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Orgenesis's Shiller PE Ratio falls into.



Orgenesis Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Orgenesis's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Orgenesis's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.16/129.4194*129.4194
=-1.160

Current CPI (Dec. 2023) = 129.4194.

Orgenesis Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201402 -0.120 99.057 -0.157
201405 -0.360 100.373 -0.464
201408 -0.720 100.352 -0.929
201411 0.000 99.635 0.000
201502 -0.240 99.032 -0.314
201505 -0.360 100.333 -0.464
201508 -0.480 100.548 -0.618
201511 -0.240 100.135 -0.310
201602 0.012 100.040 0.016
201605 -0.480 101.355 -0.613
201608 -0.240 101.617 -0.306
201611 -0.580 101.829 -0.737
201702 -0.660 102.779 -0.831
201705 -0.260 103.256 -0.326
201708 -0.400 103.587 -0.500
201711 0.030 104.072 0.037
201802 -0.520 105.052 -0.641
201805 -0.200 106.148 -0.244
201808 -0.350 106.383 -0.426
201811 -0.390 106.338 -0.475
201903 -0.550 107.251 -0.664
201906 -0.360 108.070 -0.431
201909 -0.440 108.329 -0.526
201912 -0.420 108.420 -0.501
202003 4.230 108.902 5.027
202006 -0.950 108.767 -1.130
202009 -0.110 109.815 -0.130
202012 -2.270 109.897 -2.673
202103 -0.010 111.754 -0.012
202106 -0.110 114.631 -0.124
202109 -0.420 115.734 -0.470
202112 -0.200 117.630 -0.220
202203 -0.160 121.301 -0.171
202206 -0.220 125.017 -0.228
202209 -0.050 125.227 -0.052
202212 -0.160 125.222 -0.165
202303 -0.870 127.348 -0.884
202306 -0.150 128.729 -0.151
202309 -0.430 129.860 -0.429
202312 -1.160 129.419 -1.160

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Orgenesis  (NAS:ORGS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Orgenesis Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Orgenesis's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis (Orgenesis) Business Description

Traded in Other Exchanges
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
Executives
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452

Orgenesis (Orgenesis) Headlines

From GuruFocus